Targets › 3CL
3 programs from 3 companies in 7 trials: 4 Phase 3, 2 Phase 2, 1 Phase 4; Infectious disease; next expected readout Jul 2027.
Open in Phaseline: the race on 3CL, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Shionogi | Secutrelvir SARS-CoV-2 3CL protease inhibitor | 3CL | Phase 3 | COVID-19; SARS-CoV-2 | Jul 2027 |
| Pfizer | Nirmatrelvir (PF-07321332) SARS coronavirus 3C-like proteinase inhibitor | 3CL | Phase 3 | COVID-19; COVID-19, Long Haul | – |
| Unity Health Toronto | Paxlovid SARS-CoV-2 protease inhibitor | 3CL, NSP5 | Phase 3 | COVID-19 | – |
COVID-19 (5) COVID-19, Long Haul (1) SARS-CoV-2 (1)
small molecule (3)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.